- Home
- SABR vs CDNA Comparison
SABR vs CDNA Comparison
Compare SABR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- CDNA
- Stock Information
- Founded
- SABR 2006
- CDNA 1998
- Country
- SABR United States
- CDNA United States
- Employees
- SABR N/A
- CDNA N/A
- Industry
- SABR Computer Software: Programming Data Processing
- CDNA Medical Specialities
- Sector
- SABR Technology
- CDNA Health Care
- Exchange
- SABR Nasdaq
- CDNA Nasdaq
- Market Cap
- SABR 1.3B
- CDNA 1.1B
- IPO Year
- SABR 2014
- CDNA 2014
- Fundamental
- Price
- SABR $3.06
- CDNA $17.96
- Analyst Decision
- SABR Hold
- CDNA Buy
- Analyst Count
- SABR 3
- CDNA 8
- Target Price
- SABR $4.37
- CDNA $29.43
- AVG Volume (30 Days)
- SABR 5.2M
- CDNA 724.9K
- Earning Date
- SABR 05-01-2025
- CDNA 05-08-2025
- Dividend Yield
- SABR N/A
- CDNA N/A
- EPS Growth
- SABR N/A
- CDNA N/A
- EPS
- SABR N/A
- CDNA 0.93
- Revenue
- SABR $3,029,565,000.00
- CDNA $333,785,000.00
- Revenue This Year
- SABR $9.82
- CDNA $13.32
- Revenue Next Year
- SABR $5.41
- CDNA $14.99
- P/E Ratio
- SABR N/A
- CDNA $19.31
- Revenue Growth
- SABR 4.19
- CDNA 19.07
- 52 Week Low
- SABR $2.29
- CDNA $7.42
- 52 Week High
- SABR $4.63
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- SABR 34.20
- CDNA 38.18
- Support Level
- SABR $3.32
- CDNA $18.16
- Resistance Level
- SABR $3.59
- CDNA $20.00
- Average True Range (ATR)
- SABR 0.19
- CDNA 0.84
- MACD
- SABR -0.04
- CDNA 0.05
- Stochastic Oscillator
- SABR 5.00
- CDNA 17.74
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.